Identification

Name
Flumethasone
Accession Number
DB00663  (APRD00975)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Flumethasone is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.

Structure
Thumb
Synonyms
  • 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
  • Flumetasona
  • Flumétasone
  • Flumetasone
  • Flumetasonum
External IDs
NSC-54702 / RS 2177 / U 10974 / U-10,974 / U-10974
Product Ingredients
IngredientUNIICASInChI Key
Flumethasone acetateNot AvailableNot AvailableNot applicable
Flumethasone pivalate0DV09X6F21 2002-29-1JWRMHDSINXPDHB-OJAGFMMFSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Locacorten .03%Cream.03 %TopicalNovartis1966-12-311999-05-19Canada
International/Other Brands
Cerson (Riemser) / Locacorten (Novartis) / Locorten (Novartis) / Testohgen (Maeda Yakuhin)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Locacorten VioformFlumethasone (0.02 %) + Clioquinol (3 %)CreamTopicalPaladin Labs Inc1968-12-31Not applicableCanada
Locacorten VioformFlumethasone (.02 %) + Clioquinol (3 %)OintmentTopicalNovartis1968-12-311998-05-08Canada
Locacorten Vioform EardropsFlumethasone (0.02 %) + Clioquinol (1 %)Solution / dropsAuricular (otic)Paladin Labs Inc1969-12-31Not applicableCanada
LocasalenFlumethasone (.02 %) + Salicylic acid (3 %)OintmentTopicalNovartis1973-12-311999-10-31Canada
PMS-flumethasone-clioquinolFlumethasone (0.02 %) + Clioquinol (1.0 %)Solution / dropsAuricular (otic)Pharmascience IncNot applicableNot applicableCanada
Categories
UNII
LR3CD8SX89
CAS number
2135-17-3
Weight
Average: 410.458
Monoisotopic: 410.190480328
Chemical Formula
C22H28F2O5
InChI Key
WXURHACBFYSXBI-GQKYHHCASA-N
InChI
InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

For the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions

Structured Indications
Pharmacodynamics

Flumethasone pivalate is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.

Mechanism of action

Flumethasone is a glucocorticoid receptor agonist. This complex binds to the nucleus causing a variety of genetic activation and repressions. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flumethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Minimal if applied topically

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Primarily hepatic

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Can lead to signs of irritation such as burning sensation, itching or skin rash at the site of application; hypersensitivity reactions.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Flumethasone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Flumethasone.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Flumethasone.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flumethasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Flumethasone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Flumethasone.Approved, Withdrawn
AldesleukinFlumethasone may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Flumethasone can be decreased when combined with Algeldrate.Experimental
AlmagateThe bioavailability of Flumethasone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Flumethasone can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Flumethasone.Experimental
AloglutamolThe bioavailability of Flumethasone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Flumethasone.Experimental
AluminiumThe bioavailability of Flumethasone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Flumethasone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Flumethasone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Flumethasone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Flumethasone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Flumethasone.Approved
AmiodaroneThe serum concentration of Flumethasone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BFlumethasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Flumethasone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Flumethasone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Flumethasone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Flumethasone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Flumethasone.Approved, Investigational
AprepitantThe serum concentration of Flumethasone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Flumethasone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Flumethasone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flumethasone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flumethasone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Flumethasone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Flumethasone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Flumethasone.Experimental
BendroflumethiazideFlumethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Flumethasone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Flumethasone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Flumethasone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Flumethasone.Experimental
Bismuth SubcitrateThe bioavailability of Flumethasone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Flumethasone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Flumethasone can be increased when it is combined with Boceprevir.Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flumethasone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Flumethasone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Flumethasone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Flumethasone.Experimental
BumetanideFlumethasone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Flumethasone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Flumethasone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Flumethasone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideFlumethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Flumethasone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Flumethasone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Flumethasone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Flumethasone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flumethasone.Approved, Investigational
CeritinibFlumethasone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flumethasone.Approved, Vet Approved
ChlorothiazideFlumethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Flumethasone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneFlumethasone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Flumethasone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Cinoxacin.Approved, Withdrawn
ClarithromycinThe serum concentration of Flumethasone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Flumethasone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Flumethasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Flumethasone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Flumethasone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Flumethasone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Flumethasone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Flumethasone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Flumethasone.Investigational
CyclopenthiazideFlumethasone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Flumethasone.Investigational
DaidzeinThe serum concentration of Flumethasone can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Flumethasone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Flumethasone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Flumethasone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Flumethasone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Flumethasone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Flumethasone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Flumethasone.Approved, Vet Approved
DienestrolThe serum concentration of Flumethasone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Flumethasone can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Flumethasone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flumethasone.Approved
DihydrotestosteroneFlumethasone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Flumethasone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Flumethasone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Flumethasone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Flumethasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Flumethasone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Flumethasone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Flumethasone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Flumethasone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Flumethasone.Approved
EquolThe serum concentration of Flumethasone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Flumethasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Flumethasone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Flumethasone can be increased when it is combined with Estrone.Approved
Etacrynic acidFlumethasone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Flumethasone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Flumethasone.Experimental
Ethinyl EstradiolThe serum concentration of Flumethasone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Flumethasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Flumethasone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Flumethasone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Flumethasone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Flumethasone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Flumethasone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Flumethasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flumethasone.Approved
FenthionThe risk or severity of adverse effects can be increased when Flumethasone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Flumethasone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Flumethasone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Flumethasone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Flumethasone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Flumethasone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Flumethasone.Experimental
FluoxymesteroneFlumethasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Flumethasone.Approved, Investigational
FosaprepitantThe serum concentration of Flumethasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Flumethasone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideFlumethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Flumethasone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Flumethasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Flumethasone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Flumethasone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Flumethasone is combined with Ginkgo biloba.Approved, Nutraceutical
GLPG-0492Flumethasone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Flumethasone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Flumethasone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Flumethasone.Experimental
HexestrolThe serum concentration of Flumethasone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Flumethasone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Flumethasone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flumethasone.Approved, Investigational
HydrochlorothiazideFlumethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFlumethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of Flumethasone can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Flumethasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Flumethasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Flumethasone.Approved
IdelalisibThe serum concentration of Flumethasone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Flumethasone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Flumethasone.Approved
IndapamideFlumethasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Flumethasone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Flumethasone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flumethasone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Flumethasone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Flumethasone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Flumethasone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Flumethasone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Flumethasone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Flumethasone.Withdrawn
ItraconazoleThe serum concentration of Flumethasone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Flumethasone.Experimental
KetoconazoleThe serum concentration of Flumethasone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Flumethasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Flumethasone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Flumethasone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Flumethasone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Flumethasone.Experimental
LopinavirThe serum concentration of Flumethasone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Flumethasone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Flumethasone.Approved
LumacaftorThe serum concentration of Flumethasone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Flumethasone.Approved, Investigational
MagaldrateThe bioavailability of Flumethasone can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of Flumethasone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Flumethasone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Flumethasone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flumethasone.Approved
Magnesium silicateThe bioavailability of Flumethasone can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of Flumethasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Flumethasone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flumethasone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flumethasone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Flumethasone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Flumethasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Flumethasone.Approved
MesteroloneFlumethasone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Flumethasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Flumethasone.Withdrawn
MethallenestrilThe serum concentration of Flumethasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Flumethasone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFlumethasone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Flumethasone is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteroneFlumethasone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Flumethasone is combined with Metoclopramide.Approved, Investigational
MetolazoneFlumethasone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Flumethasone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Minaprine.Approved
MitotaneThe serum concentration of Flumethasone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Flumethasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flumethasone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Flumethasone.Experimental
MoxestrolThe serum concentration of Flumethasone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flumethasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flumethasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Flumethasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Flumethasone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Flumethasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Flumethasone is combined with Nalidixic Acid.Approved
NandroloneFlumethasone may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Flumethasone.Approved, Vet Approved
NefazodoneThe serum concentration of Flumethasone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Flumethasone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Flumethasone.Approved
NevirapineThe serum concentration of Flumethasone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Flumethasone is combined with Nicorandil.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Flumethasone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Flumethasone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flumethasone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Flumethasone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flumethasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flumethasone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Flumethasone.Vet Approved
OxandroloneFlumethasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flumethasone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Flumethasone is combined with Oxolinic acid.Experimental
OxymetholoneFlumethasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flumethasone.Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Flumethasone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Flumethasone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Flumethasone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Flumethasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Flumethasone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Flumethasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flumethasone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Flumethasone.Approved, Investigational
PhenytoinThe serum concentration of Flumethasone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Flumethasone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Flumethasone is combined with Pipemidic acid.Experimental
PiretanideFlumethasone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flumethasone.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Flumethasone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flumethasone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Flumethasone.Experimental
Polyestradiol phosphateThe serum concentration of Flumethasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFlumethasone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Flumethasone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Flumethasone.Experimental
PrimidoneThe serum concentration of Flumethasone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Flumethasone.Experimental
PromestrieneThe serum concentration of Flumethasone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Flumethasone.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Flumethasone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Flumethasone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Flumethasone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Flumethasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneFlumethasone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Flumethasone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flumethasone.Experimental, Investigational
RifabutinThe serum concentration of Flumethasone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Flumethasone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Flumethasone can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Flumethasone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Flumethasone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rosoxacin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flumethasone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Flumethasone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Flumethasone.Approved
SaquinavirThe serum concentration of Flumethasone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Flumethasone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Flumethasone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Flumethasone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Flumethasone.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Sitafloxacin.Experimental
SparfloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Flumethasone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Flumethasone.Investigational
St. John's WortThe serum concentration of Flumethasone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololFlumethasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Flumethasone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flumethasone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Flumethasone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Flumethasone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Flumethasone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Flumethasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Flumethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Tacrine.Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Flumethasone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Flumethasone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Flumethasone.Withdrawn
TelithromycinThe serum concentration of Flumethasone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Flumethasone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Flumethasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Flumethasone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Flumethasone.Approved
TestosteroneFlumethasone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Flumethasone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Flumethasone.Approved
TiboloneThe serum concentration of Flumethasone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Flumethasone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Flumethasone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flumethasone.Approved
TorasemideFlumethasone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Flumethasone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Flumethasone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Flumethasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideFlumethasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Flumethasone.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Flumethasone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Flumethasone.Investigational, Withdrawn
VoriconazoleThe serum concentration of Flumethasone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinFlumethasone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Flumethasone.Approved
ZeranolThe serum concentration of Flumethasone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Flumethasone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flumethasone.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Flumethasone is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Lincoln, F.H., Schneider, W.P. and Spero, G.B.; U.S. Patent 3,557,158; January 19, 1971; assigned to The Upjohn Co.

General References
Not Available
External Links
KEGG Drug
D04208
KEGG Compound
C14479
ChemSpider
15632
ChEBI
34764
ChEMBL
CHEMBL1201392
Therapeutic Targets Database
DAP000814
PharmGKB
PA164749388
ATC Codes
D07AB03 — FlumetasoneD07XB01 — FlumetasoneS02CA02 — Flumetasone and antiinfectivesD07BB01 — Flumetasone and antisepticsD07CB05 — Flumetasone and antibiotics
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical.03 %
CreamTopical
Solution / dropsAuricular (otic)
OintmentTopical
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)219 °C (base only)Not Available
water solubility0.392 mg/LNot Available
logP3.86HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0853 mg/mLALOGPS
logP1.91ALOGPS
logP1.34ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.32 m3·mol-1ChemAxon
Polarizability41.25 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9877
Blood Brain Barrier+0.9664
Caco-2 permeable+0.5146
P-glycoprotein substrateSubstrate0.8083
P-glycoprotein inhibitor IInhibitor0.5199
P-glycoprotein inhibitor IINon-inhibitor0.7781
Renal organic cation transporterNon-inhibitor0.8453
CYP450 2C9 substrateNon-substrate0.9008
CYP450 2D6 substrateNon-substrate0.908
CYP450 3A4 substrateSubstrate0.7477
CYP450 1A2 substrateNon-inhibitor0.9087
CYP450 2C9 inhibitorNon-inhibitor0.9052
CYP450 2D6 inhibitorNon-inhibitor0.9591
CYP450 2C19 inhibitorNon-inhibitor0.9337
CYP450 3A4 inhibitorNon-inhibitor0.7935
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9005
Ames testNon AMES toxic0.8008
CarcinogenicityNon-carcinogens0.9259
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4249 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9912
hERG inhibition (predictor II)Non-inhibitor0.6792
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0079-2891000000-1cedbe5b5cccc84ebdb1

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 8 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / 9-halo-steroid
show 24 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:34764 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Maier C, Runzler D, Schindelar J, Grabner G, Waldhausl W, Kohler G, Luger A: G-protein-coupled glucocorticoid receptors on the pituitary cell membrane. J Cell Sci. 2005 Aug 1;118(Pt 15):3353-61. [PubMed:16079279 ]
  4. Labeur M, Holsboer F: Molecular mechanisms of glucocorticoid receptor signaling. Medicina (B Aires). 2010;70(5):457-62. [PubMed:20920967 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:42